Skip to content
DraconiticResearch
Search Sources API
197,761 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BY 4.0Nutrients

Selected Dietary and Supplemental Phytochemicals in Adiposity-Based Chronic Disease: Molecular Mechanisms, Human Evidence, and Translational Gaps

  • Arguiñe Ivonne Urraza-Robledo1
  • Edmar de Jesús Díaz García2
  • Ibzan Jahzeel Salvador Ibarra3,4
  • Zoila Mora Guzmán2,5
  • Anahí Jobeth Borrás Enríquez2
  • Eduardo Pérez-Campos6
  • Laura Pérez-Campos Mayoral2
  • Daniel Gómez Hernández2
  • María del Socorro Pina-Canseco2
  • Hector Alejandro Cabrera-Fuentes7,8
  • María Teresa Hernández-Huerta2,5
8 affiliations
  1. 1Centro de Mezclas Oncológicas, Unidad Médica de Alta Especialidad No. 71, Instituto Mexicano del Seguro Social, Coahuila de Zaragoza 27000, Mexico
  2. 2Centro de Investigación Facultad de Medicina UNAM-UABJO, Facultad de Medicina y Cirugía, Universidad Autónoma “Benito Juárez” de Oaxaca, Oaxaca 68020, Mexico
  3. 3Instituto Mexicano del Seguro Social, Hospital General de Zona con Medicina Familiar No. 18, Coahuila de Zaragoza 27220, Mexico
  4. 4Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI), Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Coahuila, Coahuila de Zaragoza 25000, Mexico
  5. 5Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI), Facultad de Medicina y Cirugía, Universidad Autónoma “Benito Juárez” de Oaxaca, Oaxaca 68020, Mexico
  6. 6División de Estudios de Posgrado e Investigación, Tecnológico Nacional de México, Instituto Tecnológico de Oaxaca, Oaxaca 68030, Mexico
  7. 7R&D Group, Vice Presidency for Scientific Research and Innovation, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia
  8. 8División de Estudios de Posgrado e Investigación, Tecnológico Nacional de México, Instituto Tecnológico de Tijuana, Tijuana 22414, Baja California, Mexico
Open at sourceDOICite

Abstract

Adiposity-based chronic disease (ABCD) encompasses the health consequences of excess or dysfunctional adipose tissue. Selected phytochemicals have been investigated as potential adjuncts, but experimental pathway activity does not establish clinical benefit. This narrative review examines quercetin, chlorogenic acids, epigallocatechin-3-gallate (EGCG), and berberine, with other interventions providing context. The evidence was supplemented by targeted PubMed searches through 27 October 2026 and appraised according to experimental model, formulation, exposure, clinical relevance, and safety. Published pooled body-weight differences were −0.35 kg (95% confidence interval, −2.03 to 1.33) for quercetin, −1.30 kg (−2.07 to −0.52) for selected green-coffee/chlorogenic-acid interventions, −0.74 kg (−0.97 to −0.51) for green-tea preparations, and −0.88 kg (−1.36 to −0.39) for berberine. These source-specific estimates are not head-to-head comparisons. A small crossover trial of quercetin reported reduced hepatic fat, whereas a six-month berberine trial found no significant benefit for visceral or hepatic fat. Coffee and green-tea findings do not isolate the effects of chlorogenic acid or EGCG. Most mechanistic evidence remains preclinical, and differences in chemical composition, circulating metabolites, administration, and outcome selection limit translation. The human-evidence-based selection also underrepresents less-studied phytochemicals; for the evaluated interventions, sustained adiposity reduction and patient-relevant benefit remain insufficiently established. Their potential role in comprehensive ABCD care requires product-specific assessment of efficacy, exposure, adverse effects, and interactions.

Related

  1. Editorial: Phytochemicals: molecular mechanisms for anti-aging and aging-related diseases
    Chenghao Lv, Nattaya Konsue, Si Qin
    Frontiers in NutritionPeer-reviewedCC BYFull textNutritionDOAJ
  2. Dietary phytochemicals targeting neuroinflammation: mechanisms, bioavailability and translational challenges
    Kumar M. R. Bhat, Raghavendra Upadhya, Aashika Nayak +5
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textNeurologyCrossrefDOAJ
  3. Hepatoprotective natural polyphenol extracts: molecular mechanisms, stabilization-delivery strategies, and translational bottlenecks for functional food applications
    Xiaoxiao Yao, Ruining Zhang, Yi Wang +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineCrossrefDOAJ
  4. Stem Cell-Based Therapies in Companion Animals: Molecular Mechanisms, Clinical Applications, and Translational Perspectives
    Weina Liu, Yu Wang, Wei An +7
    CellsPeer-reviewedCC BY 4.0Full textHuman geneticsCrossrefEurope PMC
  5. Aldosterone-Mediated Atrial Remodeling and Atrial Fibrillation: Molecular Mechanisms, Translational Insights and Implications for Cardiac Surgery
    Debora Emanuela Torre, Carmelo Pirri
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Cardiovascular medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{urrazarobledo2026selected,
  title = {{Selected Dietary and Supplemental Phytochemicals in Adiposity-Based Chronic Disease: Molecular Mechanisms, Human Evidence, and Translational Gaps}},
  author = {Arguiñe Ivonne Urraza-Robledo and Edmar de Jesús Díaz García and Ibzan Jahzeel Salvador Ibarra and Zoila Mora Guzmán and Anahí Jobeth Borrás Enríquez and Eduardo Pérez-Campos and Laura Pérez-Campos Mayoral and Daniel Gómez Hernández and María del Socorro Pina-Canseco and Hector Alejandro Cabrera-Fuentes and María Teresa Hernández-Huerta},
  journal = {Nutrients},
  year = {2026},
  month = oct,
  doi = {10.3390/nu18213630},
  url = {https://www.mdpi.com/2072-6643/18/21/3630},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Selected Dietary and Supplemental Phytochemicals in Adiposity-Based Chronic Disease: Molecular Mechanisms, Human Evidence, and Translational Gaps
AU  - Arguiñe Ivonne Urraza-Robledo
AU  - Edmar de Jesús Díaz García
AU  - Ibzan Jahzeel Salvador Ibarra
AU  - Zoila Mora Guzmán
AU  - Anahí Jobeth Borrás Enríquez
AU  - Eduardo Pérez-Campos
AU  - Laura Pérez-Campos Mayoral
AU  - Daniel Gómez Hernández
AU  - María del Socorro Pina-Canseco
AU  - Hector Alejandro Cabrera-Fuentes
AU  - María Teresa Hernández-Huerta
PY  - 2026
DA  - 2026/10/31
JO  - Nutrients
DO  - 10.3390/nu18213630
UR  - https://www.mdpi.com/2072-6643/18/21/3630
AB  - Adiposity-based chronic disease (ABCD) encompasses the health consequences of excess or dysfunctional adipose tissue. Selected phytochemicals have been investigated as potential adjuncts, but experimental pathway activity does not establish clinical benefit. This narrative review examines quercetin, chlorogenic acids, epigallocatechin-3-gallate (EGCG), and berberine, with other interventions providing context. The evidence was supplemented by targeted PubMed searches through 27 October 2026 and appraised according to experimental model, formulation, exposure, clinical relevance, and safety. Published pooled body-weight differences were −0.35 kg (95% confidence interval, −2.03 to 1.33) for quercetin, −1.30 kg (−2.07 to −0.52) for selected green-coffee/chlorogenic-acid interventions, −0.74 kg (−0.97 to −0.51) for green-tea preparations, and −0.88 kg (−1.36 to −0.39) for berberine. These source-specific estimates are not head-to-head comparisons. A small crossover trial of quercetin reported reduced hepatic fat, whereas a six-month berberine trial found no significant benefit for visceral or hepatic fat. Coffee and green-tea findings do not isolate the effects of chlorogenic acid or EGCG. Most mechanistic evidence remains preclinical, and differences in chemical composition, circulating metabolites, administration, and outcome selection limit translation. The human-evidence-based selection also underrepresents less-studied phytochemicals; for the evaluated interventions, sustained adiposity reduction and patient-relevant benefit remain insufficiently established. Their potential role in comprehensive ABCD care requires product-specific assessment of efficacy, exposure, adverse effects, and interactions.
SN  - 2072-6643
ER  -